Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) Research & Development (2020 - 2025)

BioAtla (BCAB) has disclosed Research & Development for 6 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • For Q4 2025, Research & Development fell 31.37% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $43.6 million, down 30.94%, while the annual FY2025 figure was $43.6 million, 30.94% down from the prior year.
  • Research & Development hit $8.0 million in Q4 2025 for BioAtla, down from $9.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $31.0 million in Q2 2023 and bottomed at $8.0 million in Q4 2025.
  • Average Research & Development over 5 years is $17.4 million, with a median of $16.5 million recorded in 2021.
  • Year-over-year, Research & Development skyrocketed 527.51% in 2021 and then tumbled 48.62% in 2024.
  • BioAtla's Research & Development stood at $16.4 million in 2021, then soared by 32.99% to $21.9 million in 2022, then grew by 3.66% to $22.7 million in 2023, then plummeted by 48.62% to $11.6 million in 2024, then crashed by 31.37% to $8.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $8.0 million, $9.5 million, and $13.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.